• W Beischer, J C Dembski, J D Gruss, F Hofgärtner, A Horsch, S Horsch, H W Kuhlmann, D A Loose, A Mietaschk, E D Schwilden, F Spengel, W Spitzer, P Staben, B Stallkamp, C S Stürzebecher, M Tokhi, and P von Bilderling.
• Klinische Entwicklung Herz-Kreislauf und Zentrales Nervensystem, Schering AG, Berlin.
• VASA. 1998 Feb 1; 27 (1): 15-9.

BackgroundIntravenous iloprost, titrated from 0.5 up to 2.0 ng/kg/min has been shown in patients with PAOD III/IV to significantly improve healing of trophic lesions, relief of rest pain, and reduce the rate of major amputation or death at 6 months as compared to placebo. The effect is considered related to improvement of the microcirculation. The aim of the present trial was to identify an optimum dose regarding treatment response and tolerability, by studying 4 doses of 25, 50, 75 and 100 micrograms iloprost daily.Patients And Methods302 patients with PAOD IV were randomised via a double-blind fashion to one of the 4 doses. The primary endpoint was the responder rate at end of treatment. Responders were defined as patients with very good or good global efficacy, as judged by lesion healing and pain relief. Side effects were documented and a pre-defined benefit/risk index was calculated.ResultsNo dose-dependency of iloprost regarding primary or secondary endpoints was observed. The rate of responders ranged between 48.7-53.5%. Side effects, mainly related to vasodilation, increased dose-dependently (p < 0.001, chi 2-test), with a significant decrease of the benefit/risk index from 2.19 +/- 1.19 to 1.64 +/- 0.97 (p = 0.012, ANOVA). Responders had a better outcome at 6 months than non-responders (2.6 fold higher rate of major amputation or death; life table analysis).ConclusionsIt is concluded that iloprost should be titrated to the optimum rather than maximum tolerated dose, since a higher incidence of side effects not associated with an increased treatment response was observed at higher doses.

27 keywords...

hide…